Patients with classical Hodgkin lymphoma whose cancer had failed to respond to other treatments showed improvement in studies that tested the effect of two PD-1 inhibitors – immunotherapy drugs that help the immune system recognize and attack cancer.
The results of the two phase 1 trials are being presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, CA.
The trial investigators – including members from Memorial Sloan Kettering Cancer Center (MSK) in New York, NY – also report one of the trials in the New England Journal of Medicine.
Lymphoma is a disease where white blood cells or lymphocytes become cancerous and grow uncontrollably. There are two main types of lymphoma – Hodgkin lymphoma and non-Hodgkin lymphoma, the latter being far more common.
Classical Hodgkin lymphoma is the most common form of Hodgkin lymphoma.
The two studies tested the effects of two PD-1 inhibitors – pembrolizumab and nivolumab – in patients with classical Hodgkin lymphoma. PD-1 inhibitors are an example of immunotherapy – drugs that help the patient’s immune system fight disease.
PD-1 inhibitors are drugs that block PD-1, a protein on the surface of T-cells that deactivates the cells. T-cells are a type of lymphocyte or white blood cell that help the immune system recognize and eliminate cancer cells and other potentially damaging material.
Some cancer cells – like those in melanoma and Hodgkin lymphoma – escape attack from the immune system by switching on PD-1 on T-cells – effectively sending these soldiers of the immune system to sleep. PD-1 inhibitors wake them up again so they can keep fighting the cancer cells.
The pembrolizumab trial found that 66% of the Hodgkin lymphoma patients who received the PD-1 inhibitor had a complete or partial response. In the trial that tested the other PD-1 inhibitor nivolumab, patients showed similar positive results.
The investigators believe the findings show immunotherapy – a relatively new approach to fighting cancer – holds huge promise for the treatment of Hodgkin lymphoma and a range of other blood disorders.
Craig H. Moskowitz, Clinical Director of MSK’s Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center, led the pembrolizumab trial. He says:
“These results are quite extraordinary given the dire circumstances these patients were facing. Pembrolizumab has already been approved for patients with advanced melanoma and we’re excited that the drug is producing responses in other cancer types.”
For the pembrolizumab trial, the investigators enrolled 29 classical Hodgkin lymphoma patients whose cancer had not responded to treatment with brentuximab vedotin. Twenty of the patients had also relapsed after stem cell treatment.
After 12 weeks, six of the patients (21% of the group) showed a complete response and 13 patients (45%) showed partial remission.
The investigators say no serious side effects were reported and only one patient stopped having treatment after experiencing a moderate adverse effect.
In the second study, investigators enrolled 23 classical Hodgkin lymphoma patients whose cancer had not responded to treatment – including 18 who had also relapsed after stem cell treatment – and gave them nivolumab.
After 24 weeks, four patients (17% of the group) had a completed response and 16 (70%) had a partial remission. Three serious side effects were reported.
Dr. Alexander M. Lesokhin, a medical oncologist at MSK and co-lead investigator of the nivolumab study, says:
“These data are the first to be reported for a completed study of a PD-1 inhibitor in classical Hodgkin lymphoma. This is good news for Hodgkin lymphoma patients and for the advancement of immunotherapies.”
The Food and Drug Administration has given nivolumab Breakthrough Therapy Designation in relapsed cHL as a result of these findings.
The teams are now planning further trials to test the drugs in larger groups of patients.
In June 2014, Medical News Today reported how a new immunotherapy that combined nivolumab and ipilimumab showed promising results in a phase 1 trial in patients with advanced melanoma.